GSK vs. Andrx Wellbutrin SR Appeal Turns On Role Of Excipient
Executive Summary
GlaxoSmithKline's Wellbutrin SR and Zyban patents do not cover the low-density form of the excipient HPMC used in Andrx' ANDA product, the generic company argued during a federal circuit appeals court hearing in Washington, D.C. Dec. 2
You may also be interested in...
Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK
An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims
Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK
An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims
Wellbutrin SR Patent Cases: Did GSK Surrender Claims To Excipients?
GlaxoSmithKline's patent infringement cases against Impax and Excel regarding Wellbutrin SR and Zyban appear to hinge on whether excipients used by the generic firms were "foreseeable.